The corticotropin releasing factor (CRF) type 1 receptor (CRF 1 ) is a class B family G proteincoupled receptor that regulates the hypothalamic-pituitary-adrenal stress axis. Astressin is an amino-terminally truncated analog of CRF that retains high affinity binding to the extracellular domain of the receptor and is believed to act as a neutral competitive antagonist of receptor activation. Here we show that despite being unable to activate the CRF 1 receptor, astressin binding results in the internalization of the receptor. Furthermore, entirely different pathways of internalization of CRF 1 receptors are utilized following CRF and astressin binding. CRF causes the receptor to be phosphorylated, recruit βarrestin2 and to be internalized rapidly, likely through clathrincoated pits. Astressin, however, fails to induce receptor phosphorylation or βarrestin2 recruitment, and internalization is slow and occurs through a pathway that is insensitive to inhibitors of clathrin-coated pits and caveolae. The fate of the internalized receptors also differs since only CRF-induced internalization results in receptor downregulation. Furthermore, we present evidence that for astressin to induce internalization it must interact with both the extracellular amino terminus and the juxtamembrane domain of the receptor. Astressin binds with 6-fold higher affinity to full length CRF 1 receptors than to a chimeric protein containing only the extracellular domain attached to the transmembrane domain of the activin IIB receptor, yet two 12-residue analogs of astressin have similar affinities for both proteins but are unable to induce receptor internalization. These data demonstrate that agonists and antagonists for CRF 1 receptors promote distinct conformations, which are then differentially regulated.
The corticotropin releasing factor (CRF) type 1 receptor (CRF 1 ) is a class B family G proteincoupled receptor that regulates the hypothalamic-pituitary-adrenal stress axis. Astressin is an amino-terminally truncated analog of CRF that retains high affinity binding to the extracellular domain of the receptor and is believed to act as a neutral competitive antagonist of receptor activation. Here we show that despite being unable to activate the CRF 1 receptor, astressin binding results in the internalization of the receptor. Furthermore, entirely different pathways of internalization of CRF 1 receptors are utilized following CRF and astressin binding. CRF causes the receptor to be phosphorylated, recruit βarrestin2 and to be internalized rapidly, likely through clathrincoated pits. Astressin, however, fails to induce receptor phosphorylation or βarrestin2 recruitment, and internalization is slow and occurs through a pathway that is insensitive to inhibitors of clathrin-coated pits and caveolae. The fate of the internalized receptors also differs since only CRF-induced internalization results in receptor downregulation. Furthermore, we present evidence that for astressin to induce internalization it must interact with both the extracellular amino terminus and the juxtamembrane domain of the receptor. Astressin binds with 6-fold higher affinity to full length CRF 1 receptors than to a chimeric protein containing only the extracellular domain attached to the transmembrane domain of the activin IIB receptor, yet two 12-residue analogs of astressin have similar affinities for both proteins but are unable to induce receptor internalization. These data demonstrate that agonists and antagonists for CRF 1 receptors promote distinct conformations, which are then differentially regulated.
The 41 amino acid neuropeptide corticotropin releasing factor (CRF) is the principal regulator of the hypothalamic-pituitaryadrenal axis, and as such plays a critical role in mediating the body's response to stress (1, 2) . In mammals, CRF and the related urocortins (UCN) 1, 2 and 3 bind to and activate two distinct G protein-coupled receptors (GPCRs), termed CRF 1 and CRF 2 (3) . The CRF 1 receptor is expressed mainly in the pituitary and central nervous system, where it is responsible for most of the central functions of CRF and UCN 1, including integration of endocrine, autonomic and behavioral responses to stress, and adrenocorticotrophic hormone (ACTH) release from corticotrope cells of the anterior pituitary (4) . Furthermore, there is strong evidence that alterations in the CRF 1 receptor system occur in many anxiety and depressive disorders(5-7). CRF 2 receptors bind all three UCNs with high affinity and CRF with lower affinity (3) . These receptors exist as three independent isoforms (CRF 2(a) , CRF 2(b) and CRF 2(c) ) and are expressed both in the central nervous system and the periphery, including in the heart, skeletal muscle, gastrointestinal tract and epididymis (3) . The functions performed by the various isoforms of the CRF 2 receptor are currently being elucidated (8) .
Both CRF 1 and CRF 2 receptors belong to the Class B family of G protein-coupled receptors, which includes (but is not limited to) the receptors for glucagon, parathyroid hormone (PTH), secretin CRF 1 Receptor Internalization By Antagonists and vasoactive intestinal peptide. All class B receptors possess a large extracellular domain (ECD) with which they bind with high affinity to the carboxyl terminal regions of their peptide ligands (9) . This interaction alone is not sufficient to stimulate coupling of the receptor to G proteins, however, and a second interaction must occur between the juxtamembrane domain of the receptor (the transmembrane helices and intervening loops) and the first few residues within the amino terminal portion of the peptide ligand (7, 10) . Since discrete regions of class B ligands perform high affinity binding and receptor stimulation, truncating the endogenous peptides at their amino termini produces high affinity competitive antagonists for class B receptors. Further modifications made to CRF truncated in this manner have produced a number of different antagonist peptides including astressin (cyclo (30) (31) (32) (33) ), a high affinity antagonist for CRF 1 receptors that also possesses enhanced biological stability, allowing its extensive use in vivo to dissect the functions of the CRF system (11, 12) . Astressin has no detectable agonist activity at the CRF 1 receptor and thus it is believed to act as a neutral competitive antagonist. In addition to binding to the ECD of CRF 1 receptors, a recent report has suggested astressin may form a second low affinity contact with the juxtamembrane domain since astressin retains the ability to inhibit CRF activation of a CRF 1 receptor fragment that lacks the ECD (13) .
Following activation by agonists, almost all GPCRs undergo a series of modifications to prevent continuous signaling of the receptor, and to enable the cells on which they are expressed to regulate their sensitivity to future exposures to agonist. This is achieved first by preventing the activated receptors from further interacting with G proteins (desensitization), and then by internalizing the receptors into intracellular compartments (also called sequestration or endocytosis) (14, 15) . Desensitization occurs through phosphorylation of intracellular domains of the receptor by GPCR kinases (GRKs) that specifically recognize agonist-occupied receptor molecules, followed by the recruitment and binding of βarrestins, which sterically hinder further receptor-G protein coupling. The subsequent internalization of the receptors can occur through multiple pathways, the most common of which utilize clathrin-coated pits and caveolae, although some less well-defined pathways have also been described, including those that use non-coated vesicles and macropinosomes (16) . Internalization can result in either short or long-term reductions in sensitivity to further agonist stimulation depending on whether the receptors become resensitized and recycle back to the cell surface, or are targeted for degradation (downregulated)(17).
A few examples of GPCRs undergoing regulation by antagonists have also been described, including internalization and downregulation of the 5HT 2A receptor by several atypical antipsychotics (18, 19) ; downregulation of the gonadotropin releasing hormone receptor (GnRHR) in pituitary gonadotrophs by the GnRH analogue cetrorelix (20) ; and phosphorylation and internalization of angiotensin II type 1A receptor (AT 1A ) by several antagonist peptide analogs of angiotensin II (21, 22) . Furthermore, it has recently been reported that the class B PTH 1 receptor also undergoes internalization following binding to the truncated antagonist peptide PTH , a process that is independent of receptor activation (23) . In light of these discoveries, we investigated whether this phenomenon of peptide antagonist-induced internalization also occurs with CRF 1 receptors, and to probe the mechanism(s) underlying this process.
Methods

Materials:
Peptides were synthesized by solidphase methodology on a Beckman Coulter 990 peptide synthesizer (Fulton, CA) and purified as previously described (13) . All chemicals were purchased from Sigma-Aldrich unless otherwise stated. Tissue culture medium and reagents were from Mediatech (Herndon, VA), except fetal bovine serum (FBS) from HyClone (Logan, UT) and horse serum from Invitrogen Life Technologies (Carlsbad, CA). Renilla mulleri GFP (RmGFP) was licensed from Prolume Inc. (Pinetop, AZ). Membranes prepared from Ltk -cells expressing human CRF 1 (hCRF 1 ) receptors and from human embryonic kidney (HEK-293) cells expressing hCRF 1 , rat CRF 1 (rCRF 1 ) and rCRF 1 -ECD/activin IIB chimera receptors have been described previously (13, 24 4 , 0.2mM glutamine, 1mM sodium pyruvate, 50I.U./ml penicillin and 50µg/ml streptomycin) and then incubated for one hour at 4°C with anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MO) diluted 1:500 in internalization medium. The cells were then washed three times with ice-cold internalization medium and incubated at 4°C in the dark for a further 30 minutes with goat anti-mouse IgG antibody conjugated to AlexaFluor™488 dye (Molecular Probes, Eugene, OR) diluted to 1:250 in internalization medium. Cells were subsequently washed with ice-cold PBS three times, detached from the dishes with PBS containing 5mM EDTA and fixed by the addition of formaldehyde to 0.8% w/v. The fluorescence intensity of 10 4 cells from each well was then measured on a FACScan™ flow cytometer (BD Biosciences, San Jose, CA). Concanavalin A (Sigma) was added to the cells at 0.25mg/ml 1 hour prior to stimulation. Hypertonic medium treatment, potassium depletion and disruption of caveolae with filipin III were carried out using previously described methods (27) (28) (29) .
Examination of Receptor internalization by Fluorescence
Microscopy: CRF 1 receptor internalization was visualized using a previously described method with a minor modification (30 ® EDTA-free protease inhibitor cocktail, Roche) for 30 minutes at 4°C with constant agitation. Detergent insoluble fractions were sedimented by 10 min centrifugation at 2,000xg, and the amount of CRF 1 receptor present in the clarified cell lysates was quantified by ELISA. Briefly, protein concentration was measured using the BCA protein assay method (Pierce, Rockford, IL). Equal amounts of protein (12µg/well) were transferred to anti-FLAG M2 coated 96-well plates (Sigma-Aldrich, St. Louis, MO) and incubated overnight at 4°C. Each well was washed 4 times with ELISA wash buffer (0.05% v/v Tween-20 in PBS), incubated for 2 hours at room temperature with the previously described anti-CRF 1 receptor antiserum 4467a-CRF 1 (31) diluted 1:10,000 in antibody dilution buffer (PBS containing 1% w/v BSA). The plates were washed, incubated for 1 hour at room temperature with horseradish peroxidase-conjugated anti-rabbit IgG (Amersham Biosciences) diluted 1:2,000 in antibody dilution buffer, followed by a final four washes. Plates were incubated with 200µl/well of ready-to-use horseradish peroxidase substrate 3,3',5,5'-tetramethylbenzidine (Sigma-Aldrich) for 30 minutes at room temperature, followed by addition of 100µl/well 0.5M H 2 SO 4 to stop the reaction.
The optical density of each well was read at 450nm using an EMax microplate reader (Molecular Devices, Sunnyvale, CA).
RESULTS
To determine whether CRF and the antagonist astressin are both capable of inducing the internalization of the CRF 1 receptor, CHO-CRF 1 cells (CHO-K1 cells stably expressing the HA-FLAG-tagged hCRF 1 receptor) were treated with 100nM CRF or astressin for between 30 minutes and 24 hours, and the loss of receptors from the cell surface was measured by flow cytometry. Time-matched vehicle-treated controls were also performed to allow all data points to be normalized to the appropriate level of cell surface expression. Figure 1A shows that both CRF and astressin induced substantial internalization over this period, however the total amount of internalization following 24 hours stimulation with CRF was greater than with astressin (71±7.4% and 51±8.1%, respectively). This difference was the result of a higher rate of receptor sequestration by CRF in the first hour of stimulation, (63% with CRF, 17% with astressin), after which sequestration by both peptides proceeded at similar rates (evident from the similar slopes of the graphs between 2 and 24 hours in Fig. 1A ). Full dose-response relationships were then produced for CRF and astressin to allow the EC 50 values to be calculated (Fig 1B) . Both peptides internalized CRF 1 receptor in a dose-dependent manner, however, despite the fact that astressin possessed only partial efficacy in the internalization assay, astressin and CRF promoted internalization with almost identical potencies (EC 50 = 7.6nM and 7.8nM, respectively). Taken together, these data indicate that the agonist CRF possess high efficacy for internalizing CRF 1 receptors, while the antagonist astressin appears to possess only partial efficacy. Despite this difference in internalization efficacy, astressin and CRF were equipotent for this effect.
We next determined whether the phenomenon of astressin-induced internalization also occurred in a cell line that expresses the CRF 1 receptor endogenously. Corticotropes of the anterior pituitary are major sites of CRF 1 receptor expression, where it stimulates the secretion of ACTH into the blood in response to CRF released from the hypothalamus (2, 32) . The mouse pituitary corticotrope adenoma AtT20 cell line expresses CRF 1 receptors (~100fmol/mg membrane protein, data not shown), produces cyclic AMP (25) and secretes ACTH(33) when challenged with CRF peptide. To measure CRF 1 receptor internalization, AtT20 cells were transfected with FLAG-tagged CRF 1 receptor to allow its movement to be tracked both by immunocytochemistry and by flow cytometry (Fig. 2) . Prior to treatment, immunostaining of live AtT20 cells with anti-FLAG M1 antibody conjugated to AlexaFluor™488 dye revealed substantial cell surface expression and no visible staining of intracellular receptors (not shown). The cells were then treated for 2 hours with vehicle, or with a maximal dose of CRF or astressin (10µM), and the redistribution of the immunofluorescence-stained receptors was monitored. No internalization of CRF 1 receptors was observed in cells treated with vehicle for 2 hours (Fig. 2Ai) , demonstrating that the conjugated M1 antibody alone did not induce receptor internalization. Following treatment with CRF, however, many of the labeled receptor molecules had redistributed from the cell surface into compartments within the cytosol (Fig. 2Aii) . A less robust but similar pattern of CRF 1 receptor redistribution to intracellular compartments was observed following astressin treatment, with substantial levels of receptor remaining at the cell surface (Fig. 2Aiii) . This reduced level of receptor redistribution with astressin correlated well with the amount of CRF 1 receptor internalization measured in AtT20 cells using flow cytometry (Fig. 2B) , where CRF induced internalization of 39% after 2 hours, increasing to 45% at 4 hours, while astressin internalized 9% after 2 hours and 16% after 4 hours.
The majority of GPCRs are internalized via clathrin-mediated endocytosis (16) . This process normally requires the receptors to be bound to agonist, phosphorylated by GRKs and to recruit cytosolic arrestins, however, clathrinmediated internalization following antagonist binding has also been reported (34) . Furthermore, some peptide antagonists are known to cause receptor phosphorylation without activating G protein coupling (21, 22, 34) . To determine if such mechanisms could underlie astressin-induced CRF 1 receptor internalization, we compared the ability of astressin and CRF to promote CRF 1 receptor phosphorylation and the recruitment of βarrestin2 (Fig. 3A and 3B ). CHO-CRF 1 cells were metabolically labeled with 32 P i , stimulated with 100nM astressin or CRF for between 5 minutes and 1 hour, and the amount of radioactivity incorporated into the CRF 1 receptor was assessed by autoradiography of receptor immunoprecipitates. Figure 3A shows that stimulation of cells with astressin caused no phosphorylation of the receptor at any of the time points tested. In contrast, stimulation with CRF induced robust phosphorylation of CRF 1 receptors by 5 minutes (4.27±0.28-fold over basal), peaking at 10 minutes (4.46±0.54-fold over basal) and then slowly diminishing to 2.08±0.54-fold after 1 hour. Next, we tested whether stimulation with astressin or CRF led to recruitment of cytosolic βarrestin2 to CRF 1 receptors. Cells were first transfected with expression constructs for βarrestin2-RmGFP and FL-CRF 1 receptor. Forty eight hours later, receptors expressed at the cell surface were visualized by immunostaining with anti-FLAG M1 antibody conjugated to Cy3, then the cells were stimulated with 100nM astressin or CRF for 5 or 15 minutes, and the distributions of receptor and βarrestin2 were determined by fluorescence microscopy (Fig. 3B) . Prior to stimulation, the CRF 1 receptor was only detected on the cell surface, while βarrestin2-RmGFP was evenly distributed throughout the cytosol and excluded from the nucleus. After 5 minutes of stimulation with CRF, the receptors were still present at the cell surface, however the majority of the βarrestin2-RmGFP had localized to the cell membrane and displayed a distribution that almost completely overlapped with the CRF 1 receptor. After 15 minutes, much of the receptor and βarrestin2-RmGFP had redistributed from the cell surface into punctate structures within the cytosol, again showing almost complete overlap of their distributions. This was entirely different from what was observed following astressin stimulation: no relocalization of βarrestin2-RmGFP was observed after 5 or 15 minutes stimulation, while a small amount of receptor internalization could be observed after 15 minutes in some cells (Fig. 3B) . Taken together, these data demonstrate that CRF binding to the CRF 1 receptor triggers phosphorylation of the receptor, recruitment of βarrestin2 and internalization of receptor-βarrestin2 complexes, while astressin treatment induces neither phosphorylation nor βarrestin2 recruitment, but still induces receptor internalization.
Next, we sought to identify the mechanisms by which CRF and astressin induced CRF 1 receptor endocytosis by testing their sensitivities to known inhibitors of internalization pathways. Clathrin-mediated endocytosis is sensitive to both treatment with hypertonic medium (DMEM containing 0.5M sucrose (27) ), and to potassium ion depletion (28) . CHO-CRF 1 cells were subjected to both these treatments prior to the addition of 100nM CRF or astressin for 1 hour, and internalization was measured by flow cytometry (Fig. 3C and 3D ). CRF-induced receptor internalization was strongly inhibited by both sucrose (83%), and potassium depletion (97%), the latter effect being largely reversed when potassium was replaced in the depletion buffer (compare 34.5±4.7% with potassium replacement to 47.4±2.4% when cells were maintained in medium). In contrast, neither of the treatments significantly affected astressin-induced internalization indicating that, while CRF-driven endocytosis is likely a clathrin-mediated process, astressin utilizes an entirely different endocytic pathway. Several GPCRs have been reported to internalize through caveolae, cup-like cholesterolrich membrane structures that contain large quantities of the membrane-associated protein caveolin1 and, like clathrin-coated pits, require dynamin1 to internalize receptors (35, 36) . Three approaches were taken to determine if caveolae were utilized by astressin or CRF to internalize CRF 1 receptors. Firstly, CHO-CRF 1 cells were treated with the cholesterol-depleting agent filipin III under conditions previously demonstrated to cause disruption of most of the caveolae in cells (1µg/ml filipin III for 1 hour (29)), and then receptor internalization was measured after 1 hour of stimulation with 100nM astressin or CRF. Filipin III failed to inhibit internalization induced by either peptide, suggesting caveolae were not involved (Fig. 3E) . Secondly, overexpression of the dominant negative mutant dynamin1 K44A, which is required for both caveolae-and clathrinmediated endocytosis, failed to inhibit astressininduced internalization but, as was expected, did significantly reduce internalization by CRF (Fig.  3F) . Thirdly, coexpression of CRF 1 receptors with the dominant negative S80E mutant of caveolin1 (or the phenotypically neutral S80A mutant)(26) failed to disrupt either astressin-or CRF-induced receptor internalization (Fig. 3F) . Taken together, these data indicate that cells treated with astressin utilize neither caveolae nor clathrin-coated pits to internalize CRF 1 receptors, while CRF-induced internalization likely occurs through clathrincoated pits, as demonstrated by its sensitivity to potassium depletion, hypertonic sucrose solution and K44A dynamin expression.
Following internalization many GPCRs are downregulated by trafficking to lysosomes for degradation, while others remain sequestered within intracellular compartments(17). We tested whether the use of different internalization pathways following CRF and astressin stimulation also resulted in alternative trafficking and processing of the CRF 1 receptor. An ELISA detection method was developed to measure loss of receptor protein in cell lysates at between 1 and 24 hours following stimulation with either 100nM astressin or CRF. Figure 4A shows that there was no reduction in total CRF 1 receptor protein following astressin stimulation at any of the time points tested, while stimulation with CRF showed a gradual loss of the receptor in the cells, from 83% remaining after 1 hour, dropping to 38% after 24 hours. Despite the kinetics of receptor downregulation being markedly different from those we observed for receptor internalization (Fig. 1A , and shown on Fig. 4A for comparison) , the downregulation is dependent on CRF 1 receptor internalization since cross-linking of the receptor on the cell surface with the lectin concanavalin A prior to stimulation suppressed internalization by both astressin (53% inhibited) and CRF (55% inhibited) and also inhibited CRF-stimulated downregulation of the receptor by 53% (Fig. 4B) .
We next investigated the nature of the interactions between astressin and the receptor that are required for receptor internalization. Peptide interaction with CRF 1 receptors proceeds according to a two-domain model in which the carboxyl terminal portion of the ligand binds the ECD, and the amino terminal portion binds the juxtamembrane domain. In addition to the high affinity interaction with the ECD, it was recently reported that astressin might also interact with low affinity with the juxtamembrane domain (13) . For example, astressin bound with higher affinity to the full-length receptor than to a chimera of the ECD and the single transmembrane domain of the activin IIB receptor, suggesting a second astressin binding site within the juxtamembrane domain. This raises the possibility that an interaction of astressin with the juxtamembrane domain is involved in receptor internalization. This hypothesis was tested using 12-residue carboxyl terminal astressin analogs that have been reported to bind CRF 1 receptors with high affinity (Yamada #19 and Yamada #20;(37)). These peptides lack 18 amino terminal residues of astressin and so would be predicted to bind only the ECD, according to the two-domain model described above. Indeed, both peptides bound with similar, if not slightly higher, affinity to the rat CRF 1 -ECD/activin IIB chimera than to the full-length receptor, consistent with these peptides binding predominantly, if not exclusively to the ECD (Table 1 ; since our previous experiments were conducted using hCRF 1 receptors, we also confirmed the affinities of all three peptides were similar for both rat and human forms). In contrast astressin bound with 6-fold higher affinity to the full-length receptor than the CRF 1 -ECD/activin IIB chimera, suggesting that binding is stabilized by interaction with the juxtamembrane domain (Table 1 , consistent with previous data(13)). Yamada #19 and Yamada #20 bound with high affinity to hCRF 1 receptors (Fig.  5A, Table 1 , K i = 1.3nM and 1.0nM respectively, in agreement with published values(37)). Full internalization dose-response relationships of both peptides were then compared to those for CRF and astressin and the EC 50 values were calculated (Fig.  5B) . Interestingly, while CRF and astressin potently induced internalization of the CRF 1 receptor (EC 50 of 5nM and 1nM, respectively), neither of the Yamada peptides showed any activity in this assay at concentrations up to 10µM (Fig. 5B) . These findings suggest that interaction with the ECD alone is insufficient to induce internalization. Furthermore, the structure-activity relationship of these ligands suggests that internalization involves interaction of the amino terminal region of astressin with the juxtamembrane domain of the receptor.
DISCUSSION
It is now widely recognized that most GPCRs are internalized following their stimulation with ligand, a process that prevents their persistent signaling and allows cells to regulate receptor number, and thus sensitivity to subsequent challenges with agonist. Internalization, coupled with receptor desensitization, is also an important process in the pathogenesis of several diseases, the development of tolerance to certain drugs, and may contribute to the efficacy of other therapeutics. For example, loss of β-adrenergic receptors from cardiac myocytes leads to heart disease(38), while desensitization of opioid receptors is believed to underlie tolerance to opiates (39) , and at least part of the therapeutic activity of cetrorelix is a result of its ability to downregulate the GnRH receptor (20) . The first two examples represent the well-studied "classic" mechanism of GPCR regulation following stimulation (or over-stimulation) with a native or synthetic agonist. The last example, however, is more interesting since it results from the binding of an antagonist to the receptor, causing the receptor to become downregulated without it ever being activated. Since current models of receptor regulation involve a priori activation of the receptor, the existence of such antagonistmediated mechanisms has profound implications for our present understanding of how GPCRs function and are regulated, and possibly for interpreting the in vivo activities of these compounds.
In this study we describe a previously unrecognized mechanism by which cells regulate CRF 1 receptors following binding to the antagonist peptide astressin, a process that promotes endocytosis of the receptor molecules and their subsequent sequestration into intracellular compartments. The mechanism by which astressin achieves this differs greatly from both the "classic" sequestration that follows stimulation with CRF, and from the mechanism used to endocytose PTH 1 following binding to PTH , the only other example of a class B receptor antagonist known to induce internalization (23) . We show here that the CRF 1 receptor undergoes rapid phosphorylation following CRF binding, probably by GRKs since GRK3 has been implicated in the regulation of these receptors (40, 41) . Similarly, phosphorylation of PTH 1 is observed when either PTH or PTH are bound, although the kinases responsible appear to be GRK2 and PKC (34, 42) . Astressin binding to CRF 1 receptors, however, does not induce any detectable level of phosphorylation, indicating the receptor does not adopt a conformation that is recognized as a substrate by GRKs. Furthermore, CRF and PTH both induce the recruitment of cytosolic βarrestins to their receptors, while neither PTH(7-34) nor astressin are capable of this (34, 42, 43) . Thus, it appears that both CRF 1 and PTH 1 receptors adopt distinct conformations following binding to their agonists or antagonists: the agonists (CRF and PTH) place both receptors into conformations that are recognized as kinase substrates and as βarrestin binding sites, and presumably become desensitized in the process; PTH(7-34) appears to be capable of placing PTH 1 into a conformation that is phosphorylated but not recognized as a binding partner by βarrestins, while astressin-bound CRF 1 receptor is neither a kinase substrate nor a βarrestin binding partner. This model of multiple receptor conformations possessing distinct signaling and regulatory properties is supported by a number of studies that demonstrate regulation and activation of GPCRs are completely separable events. For example, introduction of a zinc ion bridge between transmembrane helices 3 and 6 of PTH 1 constrains the receptor in a conformation that cannot couple to G proteins in response to agonist, but which still permits its phosphorylation and internalization (42) . Furthermore, several GPCRs for which multiple agonists or antagonists have been described undergo distinct signaling and regulatory events in a ligand-specific manner. Examples of these include the AT 1A receptor, for which there exist synthetic angiotensin II analogs capable of promoting both signaling and endocytosis, while other analogs only induce internalization (21, 22) ; the µ opioid receptor, where morphine and etorphine both potently activate signaling, but only etorphine induces receptor internalization (44, 45) ; and the chemokine receptor CCR7, where binding of only one of its two endogenous ligands promotes receptor phosphorylation and internalization, whilst both fully activate signaling (46) .
Most cells sequester GPCRs through clathrin-coated pits, although other pathways can also be used, for example, caveolae mediate the internalization of both endothelin A and B receptors and possibly also vasoactive intestinal peptide receptors (16) . Our study shows that CRFinduced receptor internalization is likely a clathrin-mediated process, since it is blocked by known inhibitors of clathrin-coated pit function (hypertonic sucrose solution (27) and potassium ion depletion (28)) and by over-expression of the GTPase-deficient K44A mutant of dynamin1, whose activity is required for detachment of clathrin-coated vesicles from the plasma membrane (47) . Whilst hypertonic sucrose and K44A dynamin are not specific inhibitors of clathrin-mediated endocytosis, sensitivity to both these treatments and to potassium depletion indicate that CRF-driven internalization is likely a clathrin-mediated event. In contrast, astressinmediated internalization is not affected by these treatments, indicating that an entirely different pathway is utilized. Since dynamin activity is also required for caveolae-mediated internalization (35, 36) , the lack of any effect of over-expression of K44A dynamin suggests that this is not the alternative pathway. We confirmed this by showing that neither the disruption of caveolae with filipin III (29) , nor over-expression of the caveolin1 S80E dominant negative mutant has any effect on astressin-induced endocytosis of the receptor(26). This differs from the pattern observed for PTH 1 , where clathrin-mediated endocytosis is used following both PTH and PTH(7-34) binding (23, 34) . However, the use of distinct endocytic pathways for the same receptor in response to multiple ligands has been described for other GPCRs, including CXCR3, where two of the three agonists (CXCL9 and CXCL10) induce internalization through a dynamin-dependent mechanism, while the third (CXCL11) does not; the nature of the alternative pathway was not investigated further (48) .
In addition to clathrin-coated pits and caveolae, cells utilize several other pathways to endocytose membrane-bound receptors, including the well-described processes of phagocytosis and fluid-phase internalization through pinocytosis, as well as some dynamin-independent mechanisms for which there are as yet no tools available to define their exact nature (49) . Furthermore, several of these ill-defined mechanisms have been implicated in the endocytosis of GPCRs, including the bradykinin type 2, N-formyl peptide and M2 muscarinic receptors (16) . It is interesting to note that the class B family receptor for secretin also internalizes in a dynamin-independent manner, raising the possibility that the CRF 1 receptor internalizes through the same mechanism, and that it may represent a general mechanism for class B receptor internalization (50) .
In addition to utilizing different paths of CRF 1 receptor internalization, we also demonstrated that astressin and CRF binding determine distinct fates for the receptor, since only CRF-bound receptors were subsequently targeted for downregulation. This process requires the receptors to be internalized first since trapping the receptors on the cell surface with the cross-linking agent concanavalin A prior to treatment with CRF inhibited their downregulation. Thus, astressin and CRF target the receptors to alternative intracellular compartments where they either remain sequestered or are downregulated. Several studies of GPCR trafficking have identified interactions between the extreme carboxyl terminal tails of GPCRs with PDZ domain-containing proteins (named after the first three proteins in which they were characterized: PSD-95/ Dlg and ZO-1) as critical for determining receptor fate following internalization(17,30,51,52). The tails of both CRF 1 and CRF 2 receptors contain putative PDZbinding motifs and therefore might also be regulated by PDZ proteins. It is interesting to note that an interaction between PTH 1 and the PDZ protein Na + /H + exchanger regulatory factor 2 (NHERF2) has been shown to inhibit PTH internalization in descending convoluted tubule cells (23) . Deletion of the PDZ-binding motif from PTH 1 relieves this inhibition and allows PTH to induce a level of receptor internalization equivalent to that observed with PTH. While we cannot discount that such a mechanism of regulation exists for CRF 1 receptors, preliminary experiments in which we truncated the C-terminal tail, in effect ablating the PDZ-binding motif, did not enhance astressin-induced internalization in either CHO-K1 or HEK-293 cells expressing the CRF 1 receptor (data not shown). However, since the identities of PDZ proteins that bind CRF 1 receptors are currently unknown, their effects on internalization or trafficking cannot be tested directly.
Finally, we have also investigated the basis of the interaction between astressin and the CRF 1 receptor responsible for inducing internalization. The existing explanation of how the CRF 1 receptor binds to peptide agonists is described by a two-domain model in which the amino terminus of the receptor binds with high affinity to the carboxyl terminal portion of the agonist, substantially increasing the local concentration of agonist and so allowing the second weak interaction to occur between the amino terminal region of the peptide and the juxtamembrane domain of the receptor (7, 10) . The exact site of this second interaction remains controversial, although contacts between peptide ligands and the second and third extracellular loops of both CRF 1 and CRF 2 receptors have been reported (53) (54) (55) (56) . Previous data suggest astressin binding is stabilized by an interaction with the juxtamembrane domain of the CRF 1 receptor. In addition, analysis of chimeric receptors suggests strong binding of antagonists to the juxtamembrane domain of CRF 2 receptors (25) . In this study we confirmed that astressin binds to the full-length CRF 1 protein with 6-fold higher affinity than to the CRF 1 -ECD/activin IIB receptor construct (Table 1 ). In contrast, two high affinity 12-residue carboxyl terminal astressin analogs (the Yamada peptides #19 and #20) bind with similar affinities to both proteins. We propose that this difference in the affinities observed for astressin is the result of an additional interaction between the juxtamembrane domain of the receptor and the extra 18 amino acids present in astressin that are absent in the Yamada peptides. Furthermore, this putative interaction appears necessary to induce the conformational change in the receptor required for its internalization, since the short Yamada analogs neither make this contact nor induce internalization.
In summary, we have demonstrated that the CRF 1 receptor is subjected to ligand-specific modes of internalization and trafficking following binding of peptide agonists and antagonists. Furthermore, we present evidence that in order for antagonist binding to promote internalization it must contact both the amino terminus and juxtamembrane domain of the receptor. These findings may have important consequences for the design of CRF 1 receptor antagonists for the treatment of anxiety disorders and depression, since they show that the receptor adopts a distinct conformation when bound to antagonists, which could be exploited to further suppress receptor signaling by inducing its internalization. 
